Teo Mario, Zhang Michael, Li Amy, Thompson Patricia A, Tayag Armine T, Wallach Jonathan, Gibbs Iris C, Soltys Scott G, Hancock Steven L, Chang Steven D
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
World Neurosurg. 2016 Sep;93:398-409. doi: 10.1016/j.wneu.2016.06.080. Epub 2016 Jun 28.
Stereotactic radiosurgery (SRS) for large vestibular schwannomas (VS) remains controversial. We studied the tumor local control and toxicity rates after hypofractionated SRS for VS > 3 cm.
A total of 587 patients with VS treated with SRS between 1998 and 2014 were reviewed retrospectively, and 30 Koos grade IV VSs were identified. There were 6 patients with neurofibromatosis 2 (NF2), 8 with cystic tumors, 22 with solid tumors, 19 who underwent primary CyberKnife (CK), and 11 with >3 cm after previous resection. Patients were treated by a median of 3 fractions at 18 Gy.
After a median 97 months, the 3- and 10-year Kaplan-Meier estimates of local control were 85% and 80%, respectively, with 20% requiring salvage treatment. For patients who had previous tumor resection rather than primary CK, the estimates were 46% and 5%, respectively, with progression, and 3-year control rates of 71% and 94% (P = 0.008). Tumor control was also lower among NF2 versus non-NF2 patients (40% vs. 95%; P = 0.0014). Among patients with good clinical baselines before CK, 88% were functionally independent (modified Rankin Scale score, 0-2), 88% had good facial function (House-Brackmann grade I-II), and 38% had serviceable hearing (Gardner-Robertson grade I-II) at last follow-up. Hearing worsening was more likely among patients treated with primary CK (33% vs. 90%; P = 0.04).
Overall, 80% of large VSs were adequately controlled by CK with 97 months of median follow-up. Patients with previous surgery and NF2 also appeared to have higher rates of tumor progression, and less favorable functional outcomes.
大型前庭神经鞘瘤(VS)的立体定向放射外科治疗(SRS)仍存在争议。我们研究了超分割SRS治疗直径>3 cm的VS后的肿瘤局部控制率和毒性率。
回顾性分析1998年至2014年间接受SRS治疗的587例VS患者,确定30例库斯IV级VS。其中神经纤维瘤病2型(NF2)患者6例,囊性肿瘤患者8例,实性肿瘤患者22例,初次接受射波刀(CK)治疗的患者19例,既往切除术后肿瘤直径>3 cm的患者11例。患者接受中位剂量为18 Gy、分3次的治疗。
中位随访97个月后,3年和10年的Kaplan-Meier局部控制估计率分别为85%和80%,20%的患者需要挽救治疗。对于既往接受过肿瘤切除术而非初次CK治疗的患者,进展后的估计率分别为46%和5%,3年控制率分别为71%和94%(P = 0.008)。NF2患者与非NF2患者相比,肿瘤控制率也较低(40%对95%;P = 0.0014)。在CK治疗前临床基线良好的患者中,末次随访时88%功能独立(改良Rankin量表评分,0 - 2),88%面部功能良好(House-Brackmann分级I - II级),3次8%听力尚可(Gardner-Robertson分级I - II级)。初次接受CK治疗的患者听力恶化的可能性更大(33%对90%;P = 0.04)。
总体而言,中位随访97个月时,80%的大型VS通过CK得到了充分控制。既往接受过手术的患者和NF2患者似乎也有较高的肿瘤进展率和较差的功能结局。